AI Analysis
AI-generated analysis. Always verify with the original filing.
Telomir Pharmaceuticals, Inc. has regained compliance with Nasdaq listing requirements following its 2025 Annual Meeting of Shareholders, resolving a prior deficiency.
Key Takeaways
1The company received a Nasdaq letter on March 30, 2026 confirming compliance with Listing Rule 5620(a).
2Compliance was achieved through holding the 2025 Annual Meeting of Shareholders.
3Nasdaq has determined the matter closed, eliminating the risk of delisting.
4The notification resolves a previously disclosed listing deficiency.